International Symposium on Adriamycin: Milan, 9th-10th September, 1971

ISBN-13: 9783642952296 / Angielski / Miękka / 2012 / 252 str.

Stephen K. Carter; A. Di Marco; M. Ghione

Opis

The impressive advances in all branches of medical science during the first half of this century with the discovery of many chemotherapeutic or immunogenic agents gave rise to brilliant achievements in the struggle against some infectious diseases and aroused in many scientists the wishful thought that drugs for cancer therapy would, soon lead to additional great success. Notwithstanding ever-increasing worldwide endeavors, the major problems in prevention or treatment of neoplastic diseases are still unsolved. The approach to the resolution of these problems follows many different pathways. Basic research tries to cast light on the genetic and biochemical processes underly ing cell division and differentiation as well as the interactions occurring between the cell and the oncogenic stimulus, or between the neoplastic cells and the different body systems endowed with immunological reactivity. Another line of approach, coherent with the classic basis of chemotherapy, relies upon the search for new compounds selectively blocking the multiplication of the neoplastic cells. The remarkable progress made in treating human cancer, as a result of these efforts, has been until now ascribable chiefly to the accomplishment of the chemo therapeutic approach. Studies on the cytostatic activity of the anthracycline antibiotics carried out over many years eventually led the investigators of Farmitalia (Milan, Italy) to discover and characterize some new compounds endowed with interesting chemotherapeutic properties against malignant neoplastic diseases."

Spis treści

Short Summary of the Informal Meeting Preceeding the Adriamycin Symposium..- I. Chemistry of Adriamycin.- Structure and Physicochemical Properties of Adriamycin (Doxorubicin)..- II. Activity at Cell Level.- Effect of Adriamycin on the Cell Kinetic of Human Bone Marrow in vitro..- Ultrastructural Alterations Induced in Hepatic Cell Nucleoli by Adriamycin..- Effects of Adriamycin on Blastogenesis and Chromosomes of Blood Lymphocytes: “in vitro” and “in vivo” Studies..- Action of Adriamycin on HeLa Cells. Evidence of a G2 Inhibition..- III Activity against Experimental Tumors.- Adriamycin: The Therapeutic Activity on Experimental Tumors..- Some Factors Influencing the Chemotherapeutic Effectiveness of Adriamycin..- Antitumor Effects of Adriamycin on Yoshida Rat Sarcoma and L 1210 Mouse Leukemia — Cross-resistance and Combination Chemotherapy..- Cross-resistance between Adriamycin, Daunomycin and Vincristine in Ehrlich Ascites Tumor in vivo..- IV. Pharmacology and Pharmacokinetics.- Influence of Pharmacokinetic Variations on the Pharmacological Properties of Adriamycin..- Pharmacokinetics and Metabolism of Adriamycin and Daunomycin..- Blood Levels, Tissue Distribution and Clinical Effects of Adriamycin..- V. Clinical Activity and Side Effects.- Adriamycin in the Treatment of Acute Leukemia..- Clinical Trials with Adriamycin. Results of a Three-Years Study..- Clinical Trials of Adriamycin. E. Frei, III, J. K. Luce, and E. Middleman.- Preliminary Results of a Clinical Trial with Intermittent Doses of Adriamycin in Lung Cancer..- Adriamycin in Adults with Neoplastic Diseases. I. H. Krakoff.- Adriamycin in the Treatment of Acute Leukemias..- Cooperative Clinical Study on Adriamycin in Advanced Lung Tumors..- Adriamycin and Daunomycin in the Treatment of Vesical and Prostatic Neoplasias. Preliminary Results..- Clinical Trial of Adriamycin..- The Effect of Adriamycin on Solid Tumors and Acute Leukemia of Adults and Children..- Adriamycin in Children with Acute Leukemia and Other Neoplastic Diseases..- Adriamycin in the Treatment of Acute Leukemia..- VI. Short Communications.- Adriamycin in Mesenchymal Tumors and Leukemias — Results of Two Years’ Research..- Preliminary Clinical Observations on the Antitumor Effect of Adriamycin..- Preliminary Clinical Trial of Adriamycin in Acute Leukemia and Solid Tumors of Children..- Combined Chemotherapy of Acute Leukemias..- Clinical Trial of Adriamycin on Malignant Diseases..- Adriamycin in the Chemotherapy of 21 Solid Tumors. Preliminary Results..- Adriamycin Use in Solid Tumors and in Lymphoblastic Leukemia of Children..- Preliminary Data on the Treatment of Hemoblastoses with Adriamycin..- Clinical Trials with Adriamycin..- Adriamycin, Vincristine and Prednisone in the Treatment of Malignant Tumors Resistant to Conventional Chemotherapy..